Equities Analysts Set Expectations for VYGR FY2029 Earnings

Voyager Therapeutics, Inc. (NASDAQ:VYGR) – Equities research analysts at Wedbush issued their FY2029 earnings estimates for shares of Voyager Therapeutics in a research note issued on Tuesday, February 11th. Wedbush analyst Y. Zhong forecasts that the company will post earnings of ($0.86) per share for the year. Wedbush has a “Outperform” rating and a $9.00 price objective on the stock. The consensus estimate for Voyager Therapeutics’ current full-year earnings is ($0.91) per share.

VYGR has been the subject of several other reports. StockNews.com cut shares of Voyager Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, December 13th. Cantor Fitzgerald initiated coverage on shares of Voyager Therapeutics in a research note on Friday, January 10th. They set an “overweight” rating and a $5.73 price objective for the company. Canaccord Genuity Group reiterated a “buy” rating and issued a $14.00 target price on shares of Voyager Therapeutics in a research note on Thursday, November 14th. HC Wainwright reiterated a “buy” rating and issued a $30.00 target price on shares of Voyager Therapeutics in a research note on Monday, January 27th. Finally, Citigroup initiated coverage on shares of Voyager Therapeutics in a research note on Monday, December 2nd. They issued a “buy” rating and a $12.00 target price for the company. One investment analyst has rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, Voyager Therapeutics currently has an average rating of “Buy” and an average price target of $15.72.

Voyager Therapeutics Trading Down 3.4 %

Shares of NASDAQ VYGR opened at $4.23 on Thursday. Voyager Therapeutics has a 12 month low of $4.00 and a 12 month high of $10.66. The company has a 50 day simple moving average of $5.57 and a two-hundred day simple moving average of $6.27. The stock has a market cap of $231.07 million, a price-to-earnings ratio of 5.96 and a beta of 0.91.

Voyager Therapeutics (NASDAQ:VYGR) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.45) by $0.29. Voyager Therapeutics had a net margin of 15.80% and a return on equity of 8.33%. The business had revenue of $24.63 million during the quarter, compared to analysts’ expectations of $12.63 million. During the same period in the previous year, the business posted ($0.59) EPS.

Institutional Investors Weigh In On Voyager Therapeutics

Large investors have recently modified their holdings of the business. Tower Research Capital LLC TRC grew its holdings in shares of Voyager Therapeutics by 133.4% during the fourth quarter. Tower Research Capital LLC TRC now owns 5,383 shares of the company’s stock worth $31,000 after buying an additional 3,077 shares in the last quarter. Picton Mahoney Asset Management grew its holdings in shares of Voyager Therapeutics by 71.1% during the fourth quarter. Picton Mahoney Asset Management now owns 5,883 shares of the company’s stock worth $33,000 after buying an additional 2,444 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in shares of Voyager Therapeutics by 64.1% during the third quarter. China Universal Asset Management Co. Ltd. now owns 10,489 shares of the company’s stock worth $61,000 after buying an additional 4,098 shares in the last quarter. Oxford Asset Management LLP purchased a new stake in shares of Voyager Therapeutics in the fourth quarter valued at about $60,000. Finally, Intech Investment Management LLC purchased a new stake in shares of Voyager Therapeutics in the third quarter valued at about $74,000. Hedge funds and other institutional investors own 48.03% of the company’s stock.

Insider Buying and Selling

In other news, COO Robin Swartz sold 6,500 shares of the company’s stock in a transaction on Monday, December 23rd. The shares were sold at an average price of $5.65, for a total transaction of $36,725.00. Following the completion of the sale, the chief operating officer now owns 112,328 shares of the company’s stock, valued at $634,653.20. This represents a 5.47 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In the last quarter, insiders sold 10,778 shares of company stock valued at $58,548. 4.53% of the stock is owned by corporate insiders.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.